Valuation: ProSomnus, Inc.

Market Cap 237K 208K 193K 177K 333K 22.78M 338K 2.29M 896K 11.2M 888K 869K 38.72M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.95M 28.79M 26.42M 49.63M 3.39B 50.4M 342M 134M 1.67B 132M 129M 5.77B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
2.2
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 03/05/2022
Chief Tech/Sci/R&D Officer 45 03/05/2022
Director of Finance/CFO 57 01/03/2023
Date Insider Type Main position Quantity % Market Cap.
2/15/24 A Free

Chief Executive Officer

1,322,756 8.0663%
2/15/24 A Free

Founder

315,742 1.9254%
2/15/24 A Free

Chief Financial Officer

315,742 1.9254%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.33% 237K
+1.42%-1.52%-18.62%+5.39% 3.59B
-2.36%-13.76%+27.25% - 1.23B
+3.87%-9.67%+11.76% - 642M
-1.15%+1.98%-3.02%-6.72% 148M
-1.04%-2.67%+58.43%+67.08% 120M
Average +0.12%-2.80%+12.64%-8.39% 955.35M
Weighted average by Cap. +0.76%-4.82%-3.33%+6.83%

Financials

2022 2023
Net sales 19.39M 17.03M 15.84M 14.54M 27.31M 1.87B 27.73M 188M 73.49M 918M 72.8M 71.23M 3.17B 27.65M 24.29M 22.59M 20.73M 38.94M 2.66B 39.54M 268M 105M 1.31B 104M 102M 4.53B
Net income -7.15M -6.28M -5.84M -5.36M -10.06M -688M -10.22M -69.3M -27.08M -338M -26.82M -26.25M -1.17B -24.1M -21.16M -19.68M -18.06M -33.93M -2.32B -34.46M -234M -91.31M -1.14B -90.45M -88.5M -3.94B
Net Debt 17.17M 15.08M 14.02M 12.87M 24.17M 1.65B 24.55M 166M 65.05M 813M 64.44M 63.05M 2.81B 35.01M 30.75M 28.59M 26.24M 49.3M 3.37B 50.06M 340M 133M 1.66B 131M 129M 5.73B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock